The DDX19B Knockout Raji Polyclonal Cells product from Ascent Research provides a CRISPR/Cas9-edited polyclonal knockout cell population designed to disrupt DDX19B gene function in a human B lymphocyte background. This polyclonal format preserves the natural heterogeneity of the Raji host cell line while introducing targeted gene disruption across the population, enabling researchers to study loss-of-function effects without clonal selection artifacts. The cells are generated using CRISPR/Cas9-mediated gene editing to achieve robust disruption of DDX19B, offering a versatile tool for investigating mRNA export mechanisms, cancer cell biology, and drug target validation in lymphoma models.
The Raji cell line, derived from a Burkitt lymphoma patient, is a well-established model for B-cell malignancies and immunological research. These suspension-adapted B lymphocytes are characterized by their rapid proliferation, Epstein-Barr virus (EBV) positivity, and capacity for antibody production, making them particularly suitable for studies of oncogenic signaling, gene expression regulation, and immune response pathways. The Raji background provides a clinically relevant context for examining the role of mRNA export factors in lymphomagenesis and B-cell biology, as this cell type is highly dependent on efficient gene expression for its growth and survival.
DDX19B encodes a DEAD-box RNA helicase that functions as a critical mediator of mRNA export from the nucleus to the cytoplasm. Positioned at the cytoplasmic face of the nuclear pore complex, DDX19B interacts directly with the nucleoporin NUP214 and associates with NUP62, facilitating the translocation of mature messenger ribonucleoprotein (mRNP) complexes through the pore. Mechanistically, DDX19B is an integral component of the TREX (transcription-export) complex, coupling transcription elongation with mRNA processing and export; it cooperates with THOC1, THOC2, and the adaptor protein ALYREF to recruit and remodel mRNPs. Its ATP-dependent helicase activity is essential for removing export factors and directionally releasing the mRNA into the cytoplasm, thereby linking nuclear processing to translational competence. Upstream, DDX19B expression and localization are subject to cell cycle-dependent regulation, ensuring precise temporal control of gene expression. Disruption of DDX19B disrupts this coordinated pathway, potentially leading to nuclear retention of polyadenylated mRNAs and global alterations in protein synthesis.
In the Raji lymphoma background, DDX19B knockout provides a powerful model to assess how mRNA export defects impact the proliferative and survival programs of malignant B cells. Given the high transcriptional and translational demand of rapidly dividing lymphoma cells, DDX19B disruption may reveal vulnerabilities in mRNA export that can be exploited therapeutically. The polyclonal knockout population enables the study of heterogeneous cellular responses, closely mimicking the clonal diversity observed in tumors. This model is well-suited for evaluating the dependency of B-cell malignancies on the mRNA export machinery, offering insights into the potential of targeting DDX19B or its interacting partners, such as NUP214 and the TREX complex, in oncogenic contexts.
This polyclonal knockout cell product is ideally suited for a range of advanced research applications. Investigators can utilize RNA-sequencing to profile transcriptomic changes resulting from impaired mRNA export, immunofluorescence microscopy to visualize nuclear mRNA accumulation, and western blotting to confirm DDX19B protein loss. Functional studies may include cell proliferation assays to assess growth defects and drug sensitivity screens to identify synthetic lethal interactions or resistance mechanisms in lymphoma. The DDX19B Knockout Raji Polyclonal Cells thus provide a robust platform for mechanistic dissection of mRNA export pathways and for validating DDX19B as a potential drug target in B-cell malignancies. For custom services or additional information, please contact Ascent Research.
